

Supplemental Table 1. Association of hypoglycemic drugs and metformin with cardiorespiratory fitness and mitochondrial oxidative capacity

	All hypoglycemic agents		Metformin	
	β estimate	p-value	β estimate	p-value
VO ₂ peak	-82.27 ± 62.24	0.19	-13.08 ± 55.47	0.81
ATPmax	-0.05 ± 0.03	0.05	-0.06 ± 0.02	0.01*
OXPHOS _{CHO}	-1.03 ± 2.01	0.61	-0.71 ± 1.81	0.70
maxOXPHOS _{CHO}	-3.52 ± 3.20	0.27	-3.11 ± 2.89	0.28
maxETS _{CHO}	-2.95 ± 4.45	0.51	-4.07 ± 4.04	0.32
OXPHOS _{FAO}	-1.35 ± 1.06	0.21	-0.68 ± 1.00	0.50
maxOXPHOS _{FAO}	-2.57 ± 3.69	0.49	-5.30 ± 3.43	0.13

β estimate ± standard error with significance accepted at **p<0.05**. Data adjusted for age, race, and site/technician. ATPmax = maximal adenosine triphosphate production, OXPHOS_{CHO} = carbohydrate supported respiration, maxOXPHOS_{CHO} = carbohydrate supported maximal complex I+II stimulated respiration, maxETS_{CHO} = carbohydrate supported maximal electron transport system, OXPHOS_{FAO} = fatty acid oxidation (FAO) supported respiration, maxOXPHOS_{FAO} = fatty acid oxidation supported maximal complex I+II stimulated respiration.